HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: A review of histopathology, diagnostic testing, and clinical implications

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 6, 2012, Pages 691-697

  Hechtman, Jaclyn F ^a   Polydorides, Alexandros D ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADENOCARCINOMA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LOWER ESOPHAGUS SPHINCTER; METABOLISM; PATHOLOGY; REVIEW; STOMACH; STOMACH TUMOR;

ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION; GENE AMPLIFICATION; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; RECEPTOR, ERBB-2; STOMACH; STOMACH NEOPLASMS;

EID: 84864239201     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2011-0168-RS     Document Type: Review

References (36)

1. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523-1529.
2. Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol. 2009;40(6):769-777.
3. Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78(1):26-33.
4. Yan B, Yau EX, Bte Omar SS, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol. 2010;63(9):839-842.
5. Fukushige S, Matsubara K, Yoshida M, et al. Localization of a novel c-erbbrelated gene, c-erbb-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol. 1986;6(3):955-958. (Pubitemid 16135959)
6. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal epithelia and gastric carcinomas. J Natl Cancer Inst. 1986; 77(5):1047-1052. (Pubitemid 17184126)
7. Gravalos C, Marquez A, García-Carbonero R, et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer patients: a prospective study [abstract 89]. Abstract presented at: 2007 Gastrointestinal Cancers Symposium, January 19-21, 2007; Orlando, Florida.
8. Lordick F, Bang YJ, Kang YK, et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer [abstract 3541]. Eur J Cancer. 2007;5(4):271.
9. Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273-278. (Pubitemid 40309309)
10. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J Clin Oncol. 2000;18(11):2201-2209. (Pubitemid 30350211)
11. Takehana T, Kunitomo K, Kono K, et al. Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002; 98(6):833-837. (Pubitemid 34286677)
12. Moelans CB, van Diest PJ, Milne AN, Offerhaus AG. Her-2/neu testing and therapy in gastroesophageal adenocarcinoma [published online ahead of print December 6, 2010]. Pathol Res Int. 2011(2011):674182.
13. Roskoski R Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun. 2004;319(1):1-11. (Pubitemid 38670153)
14. Spechler SJ, Dixon MF, Genta R, et al. Adenocarcinoma of the oesophagogastric junction. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon, France: IARC Press; 2000:29-34.
15. Polkowski W, van Sandick JW, Offerhaus GJ, et al. Prognostic value of Laurén classification and c-erbB-2 oncogene overexpression in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol. 1999;6(3): 290-297. (Pubitemid 29221016)
16. Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Nat Cancer Inst. 2009;101(19):1306-1307.
17. Yano T, Doi T, Ohtsu A, et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Oncol Rep. 2006;15(1): 65-71.
18. Roh JH, Srivastava A, Lauwers GY, et al. Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol. 2010;34(8):1139-1146.
19. Rüschoff J, Dietel M, Baretton G, et al. HER2 diagnostics in gastric cancerguideline validation and development of standardized immunohistochemical testing. Virchows Arch. 2010;457(3):299-307.
20. Ricardo SA, Milanezi F, Carvalho ST, et al. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. J Clin Pathol. 2007;60(9);1001-1005. (Pubitemid 47441932)
21. Milanezi F, Carvalho S, Schmitt FC. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy. Expert Rev Mol Diagn. 2008;8(4);417-434. (Pubitemid 351962088)
22. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131(1):18-43. (Pubitemid 46174133)
23. Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7): 797-805. (Pubitemid 351724903)
24. Jouret-Mourin A, Hoorens A, Kockx M, et al. Belgian guidelines for HER2 testing in gastric cancer. Belg J Med Oncol. 2011;5(1):14-22.
25. Barros-Silva JD, Leitão D, Afonso L, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer. 2009;100(3):487-493.
26. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet. 2010;376(9742):687-697.
27. Boers JE, Meeuwissen H, Methorst N. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology. 2009; 58(3):383-394.
28. Haas M, Buttner M, Rau TT, et al. Inflammation in gastric adenocarcinoma ofthe cardia: how do EBV infection, Her2 amplification and cancer progression influence tumor-infiltrating lymphocytes? Virchows Arch. 2011;458(4):403-411.
29. Albarello L, Pecciarini L, Doglioni C. HER2 testing in gastric cancer. Adv Anat Pathol. 2011;18(1):53-59.
30. Tanner M, Gancberg D, Leo BAD, et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol. 2000:157(5):1467-1472.
31. College of American Pathologists. Frequently asked questions about ER/PgR testing guidelines. http://www.cap.org/apps/cap.portaR-nfpb= true&cntvwrPtlt-actionOverride=%2Fportlets%2FcontentViewer%2Fshow&- windowLabel =cntvwrPtlt&cntvwrPtlt{actionForm.contentReference}= committees%2Fimmunohistochemistry%2Fher2-faqs.html&-state= maximized&-pageLabel=cntvwr#validate. Updated January 12, 2011. Accessed May 9, 2011.
32. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004;5(1):63-69. (Pubitemid 38821193)
33. Yonemura Y, Ninomiya I, Yamaguchi A, et al. Evaluation of immunore-activity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res. 1991;51(3):1034-1038.
34. Reichelt U, Duesedau P, Tsourlakis MCh, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol. 2007;20(1):120-129. (Pubitemid 44967957)
35. Wainberg ZA, Anghel A, Desai AM, et al. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo. Clin Cancer Res. 2010;16 (5):1509-1519.
36. European Medicines Agency. Committee for medicinal products for human use post-authorisation summary of positive opinion for Herceptin. www.emea.europa.eu/pdfs/human/opinion/Herceptin-82246709en.pdf. Published 2009. Accessed May 9, 2011.